Literature DB >> 12208801

Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction.

Scott D Solomon1, Martin St John Sutton, Gervasio A Lamas, Ted Plappert, Jean L Rouleau, Hicham Skali, Lemuel Moyé, Eugene Braunwald, Marc A Pfeffer.   

Abstract

BACKGROUND: Diabetic patients are at increased risk for heart failure (HF) and other adverse events after myocardial infarction (MI). Left ventricular (LV) enlargement after MI is also associated with the same increased risk. We used data from the Survival and Ventricular Enlargement (SAVE) echocardiographic substudy to test the hypothesis that diabetes was associated with increased LV enlargement after MI. METHODS AND
RESULTS: Four hundred twelve nondiabetic and 100 diabetic patients underwent echocardiographic assessment at baseline and 3 months, 1 year, and 2 years after MI. HF developed in 30% of diabetic and 17% of nondiabetic patients during follow-up (P<0.001). Baseline LV diastolic size, ejection fraction, and infarct segment length were similar between diabetic and nondiabetic patients. Diabetic patients demonstrated less LV enlargement between baseline and 2 years than nondiabetic patients (0.9+/-11.1 cm2 versus 3.8+/-10.9 cm2, P=0.047). In patients who developed HF, LV diastolic dilatation (10.0+/-12.4 cm2 versus 3.7+/-13.1 cm2, P=0.06) and systolic dilatation (4.6+/-11.8 versus 0.91+/-12.1, P=0.017) were greater in nondiabetic than in diabetic patients. LV dilatation between baseline and 2 years was a predictor of HF in nondiabetic patients, but not in diabetic patients, even after excluding patients with recurrent MI and adjusting for history of hypertension, prior MI, age, treatment group, and smoking. Diabetes modified the relationship between ventricular enlargement and the risk of HF (P=0.011).
CONCLUSIONS: The increased incidence of HF after MI in diabetic patients is not explained by a greater propensity for LV remodeling.

Entities:  

Mesh:

Year:  2002        PMID: 12208801     DOI: 10.1161/01.cir.0000032313.82552.e3

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.

Authors:  Merry L Lindsey; Rugmani Padmanabhan Iyer; Mira Jung; Kristine Y DeLeon-Pennell; Yonggang Ma
Journal:  J Mol Cell Cardiol       Date:  2015-12-23       Impact factor: 5.000

Review 2.  Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system.

Authors:  Norbert Fülöp; Richard B Marchase; John C Chatham
Journal:  Cardiovasc Res       Date:  2006-07-29       Impact factor: 10.787

Review 3.  Type 2 diabetes, mitochondrial biology and the heart.

Authors:  Michael N Sack
Journal:  J Mol Cell Cardiol       Date:  2009-02-13       Impact factor: 5.000

Review 4.  Clinical modifiers for heart failure following myocardial infarction.

Authors:  Nandan S Anavekar; Nagesh S Anavekar
Journal:  Curr Heart Fail Rep       Date:  2005-12

5.  Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study.

Authors:  Hicham Skali; Amil Shah; Deepak K Gupta; Susan Cheng; Brian Claggett; Jiankang Liu; Natalie Bello; David Aguilar; Orly Vardeny; Kunihiro Matsushita; Elizabeth Selvin; Scott Solomon
Journal:  Circ Heart Fail       Date:  2015-03-10       Impact factor: 8.790

6.  A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II.

Authors:  Souad Belmadani; Juan Bernal; Chih-Chang Wei; Manuel A Pallero; Louis Dell'italia; Joanne E Murphy-Ullrich; Kathleen H Berecek
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

7.  Augmented cardiac formation of oxidatively-induced carbonylated proteins accompanies the increased functional severity of post-myocardial infarction heart failure in the setting of type 1 diabetes mellitus.

Authors:  Kathleen E Dennis; Salisha Hill; Kristie L Rose; Uchechukwu K A Sampson; Michael F Hill
Journal:  Cardiovasc Pathol       Date:  2013-04-06       Impact factor: 2.185

Review 8.  Macrophage roles following myocardial infarction.

Authors:  Jessica M Lambert; Elizabeth F Lopez; Merry L Lindsey
Journal:  Int J Cardiol       Date:  2008-07-25       Impact factor: 4.164

9.  Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system.

Authors:  Boglarka Laczy; Bradford G Hill; Kai Wang; Andrew J Paterson; C Roger White; Dongqi Xing; Yiu-Fai Chen; Victor Darley-Usmar; Suzanne Oparil; John C Chatham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-21       Impact factor: 4.733

10.  Emerging role for antioxidant therapy in protection against diabetic cardiac complications: experimental and clinical evidence for utilization of classic and new antioxidants.

Authors:  Michael F Hill
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.